Skip to content
2000
Volume 25, Issue 13
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Denosumab, a fully humanized monoclonal neutralizing antibody inhibiting the RANK/RANKL/OPG signaling pathway, is widely used for treating patients with bone metastases. However, its use in cancer patients with bone metastases is burdened by the risk of all grades of hypocalcemia, with the severe grade being rare. In the literature, several cases of severe symptomatic hypocalcemia have been reported, particularly in patients with breast and prostate cancers. In this report, we present a rare case of asymptomatic hypocalcemia in a 78 years-old patient with sigmoid cancer and bone metastases.

Case Presentation

Hypocalcemia was detected two weeks after the first denosumab administration, during routine biochemical evaluation. The patient reported only a mild nonspecific paresthesia after medical questioning, without relevant clinical symptoms. Despite the severity of the hypocalcemia, serum calcium levels began to improve after a short period of low-dose calcium and calcitriol therapy, though complete stabilization and normalization occurred after several weeks.

Conclusion

This case highlights the importance to consider severe paucisymptomatic or asymptomatic hypocalcemia as a possible side effect in bone-metastatic patients treated with denosumab. It is advisable to monitor serum calcium levels even in the absence of typical hypocalcemia-related symptoms.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303347379241107095529
2024-12-05
2025-12-08

  • From This Site

    /content/journals/emiddt/10.2174/0118715303347379241107095529
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/13/EMIDDT-25-13-09.html?itemId=/content/journals/emiddt/10.2174/0118715303347379241107095529&mimeType=html&fmt=ahah

References

  1. KostenuikP.J. NguyenH.Q. McCabeJ. WarmingtonK.S. KuraharaC. SunN. ChenC. LiL. CattleyR.C. VanG. ScullyS. ElliottR. GrisantiM. MoronyS. TanH.L. AsuncionF. LiX. OminskyM.S. StolinaM. DwyerD. DougallW.C. HawkinsN. BoyleW.J. SimonetW.S. SullivanJ.K. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.J. Bone Miner. Res.200924218219510.1359/jbmr.08111219016581
     [Google Scholar]
  2. KendlerD.L. CosmanF. StadR.K. FerrariS. Denosumab in the treatment of osteoporosis: 10 years later: A narrative review.Adv. Ther.2022391587410.1007/s12325‑021‑01936‑y34762286
     [Google Scholar]
  3. ColemanR. HadjiP. BodyJ.J. SantiniD. ChowE. TerposE. OudardS. BrulandØ. FlamenP. KurthA. Van PoznakC. AaproM. JordanK. Bone health in cancer: ESMO Clinical Practice Guidelines.Ann. Oncol.202031121650166310.1016/j.annonc.2020.07.01932801018
     [Google Scholar]
  4. TakahashiS. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.J. Bone Miner. Metab.202341330731610.1007/s00774‑023‑01414‑137036530
     [Google Scholar]
  5. LiptonA. FizaziK. StopeckA.T. HenryD.H. BrownJ.E. YardleyD.A. RichardsonG.E. SienaS. MarotoP. ClemensM. BilynskyyB. CharuV. BeuzebocP. RaderM. ViniegraM. SaadF. KeC. BraunA. JunS. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials.Eur. J. Cancer201248163082309210.1016/j.ejca.2012.08.00222975218
     [Google Scholar]
  6. NasserS.M. SahalA. HamadA. ElazzazyS. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.J. Oncol. Pharm. Pract.20192581846185210.1177/107815521882092731694497
     [Google Scholar]
  7. FizaziK. CarducciM. SmithM. DamiãoR. BrownJ. KarshL. MileckiP. ShoreN. RaderM. WangH. JiangQ. TadrosS. DanseyR. GoesslC. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study.Lancet2011377976881382210.1016/S0140‑6736(10)62344‑621353695
     [Google Scholar]
  8. ColemanR.E. Clinical features of metastatic bone disease and risk of skeletal morbidity.Clin. Cancer Res.200612206243s6249s10.1158/1078‑0432.CCR‑06‑093117062708
     [Google Scholar]
  9. StegerG.G. BartschR. Denosumab for the treatment of bone metastases in breast cancer: Evidence and opinion.Ther. Adv. Med. Oncol.20113523324310.1177/175883401141265621957430
     [Google Scholar]
  10. TsvetovG. AmitaiO. ShochatT. ShimonI. AkirovA. CohenT. Denosumab-induced hypocalcemia in patients with osteoporosis: Can you know who will get low?Osteoporos. Int.202031465566510.1007/s00198‑019‑05261‑731838550
     [Google Scholar]
  11. HuynhA.L.H. BakerS.T. StewardsonA.J. JohnsonD.F. Denosumab-associated hypocalcaemia: Incidence, severity and patient characteristics in a tertiary hospital setting.Pharmacoepidemiol. Drug Saf.201625111274127810.1002/pds.404527255807
     [Google Scholar]
  12. VerziccoI. RegolistiG. QuainiF. BocchiP. BrusascoI. FerrariM. PasseriG. CannoneV. CoghiP. FiaccadoriE. VignaliA. VolpiR. CabassiA. Electrolyte disorders induced by antineoplastic drugs.Front. Oncol.20201077910.3389/fonc.2020.0077932509580
     [Google Scholar]
  13. FakihM.G. WildingG. LombardoJ. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.Clin. Colorectal Cancer20066215215610.3816/CCC.2006.n.03316945172
     [Google Scholar]
  14. TejparS. PiessevauxH. ClaesK. PirontP. HoenderopJ.G.J. VerslypeC. Van CutsemE. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study.Lancet Oncol.20078538739410.1016/S1470‑2045(07)70108‑017466895
     [Google Scholar]
  15. TsujiiT. OgakiT. NakaeK. ImaiK. KiseD. TadaS. UedaH. MoriyamaM. Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody.J. Pharm. Health Care Sci.2016212310.1186/s40780‑016‑0060‑927688901
     [Google Scholar]
  16. WitteveenJ.E. van ThielS. RomijnJ.A. HamdyN.A.T. Therapy of endocrine disease: Hungry bone syndrome: Still a challenge in the post-operative management of primary hyperparathyroidism: A systematic review of the literature.Eur. J. Endocrinol.20131683R45R5310.1530/EJE‑12‑052823152439
     [Google Scholar]
  17. FlorescuM. PlumbT. Smith-ShullS. NiemanJ. MandalapuP. IslamK.M. Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients.Int. J. Nephrol. Renovasc. Dis.2014718319010.2147/IJNRD.S5699524868170
     [Google Scholar]
  18. GarlaV.V. SalimS. KovvuruK.R. SubausteA. Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.BMJ Case Rep.20182018bcr201822503910.1136/bcr‑2018‑22503929982185
     [Google Scholar]
  19. NakamuraY. KamimuraM. IkegamiS. MukaiyamaK. UchiyamaS. TaguchiA. KatoH. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: A short-term study.BMC Endocr. Disord.20151518110.1186/s12902‑015‑0077‑326666998
     [Google Scholar]
  20. PittmanK. AntillY.C. GoldrickA. GohJ. de BoerR.H. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.Asia Pac. J. Clin. Oncol.201713426627610.1111/ajco.1251727862983
     [Google Scholar]
  21. BodyJ.J. BoneH.G. de BoerR.H. StopeckA. Van PoznakC. DamiãoR. FizaziK. HenryD.H. IbrahimT. LiptonA. SaadF. ShoreN. TakanoT. ShaywitzA.J. WangH. BraccoO.L. BraunA. KostenuikP.J. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.Eur. J. Cancer201551131812182110.1016/j.ejca.2015.05.01626093811
     [Google Scholar]
  22. NakamuraK. KayaM. YanagisawaY. YamamotoK. TakayashikiN. UkitaH. NaguraM. SugiueK. KitajimaM. HiranoK. IshidaH. OnodaC. KobayashiY. NakataniE. OdagiriK. SuzukiT. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: A multicenter, retrospective, observational study.BMC Cancer202424121810.1186/s12885‑024‑11942‑238360579
     [Google Scholar]
  23. DadanaS. GundepalliS. KondapalliA. Severe refractory hypocalcemia caused by denosumab.Cureus2023156e3986637404446
     [Google Scholar]
  24. AldasouqiS. GlassyC.M. GlassyM.S. TreskaA. Caldwell-McMillanM. GossainV. Asymptomatic severe hypocalcemia secondary to vitamin d deficiency in an elderly patient.Case Rep. Endocrinol.201120111310.1155/2011/83095222937291
     [Google Scholar]
  25. AjeroP.M.E. BelskyJ.L. PrawiusH.D. RellaV. Chemotherapy-induced hypocalcemia.Endocr. Pract.201016228429010.4158/EP09137.RA19789154
     [Google Scholar]
  26. McCalebR.V. JohnsonJ.T. Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation.AACE Clin. Case Rep.201951e82e8510.4158/ACCR‑2018‑029531967007
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303347379241107095529
Loading
Asymptomatic Hypocalcemia Related to Denosumab Administration in Bone-Metastatic Patient Affected by Colorectal Cancer: A Case Report
Endocr Metab Immune Disord Drug Targets 25, 1116 (2025); https://doi.org/10.2174/0118715303347379241107095529
/content/journals/emiddt/10.2174/0118715303347379241107095529
/content/journals/emiddt/10.2174/0118715303347379241107095529
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): bone metastases; cancer; colorectal cancer; Denosumab; hypocalcemia; osteoporosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test